Stay updated on Pembrolizumab & Lanreotide for GI NETs Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.

Latest updates to the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page
- Check4 days agoChange DetectedNo substantive changes to the study details or eligibility criteria are evident between the two screenshots; any differences seem to be formatting, spacing, or UI elements rather than content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check11 days agoNo Change Detected
- Check32 days agoChange DetectedMajor update: adds current operating status notice and links for NIH Clinical Center, and bumps version to v3.2.0, replacing the old v3.1.0.SummaryDifference3%

- Check40 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed. No changes to core content, pricing, stock, or scheduling.SummaryDifference0.2%

- Check61 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.2%

- Check68 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as the introduction of specific medical terms related to gastro-enteropancreatic neuroendocrine tumors and associated treatments. However, many previously listed terms and resources have been removed.SummaryDifference4%

Stay in the know with updates to Pembrolizumab & Lanreotide for GI NETs Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.